{"id":108660,"date":"2021-05-26T10:58:11","date_gmt":"2021-05-26T10:58:11","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=108660"},"modified":"2021-05-26T10:58:11","modified_gmt":"2021-05-26T10:58:11","slug":"fetal-valproate-syndrome","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/","title":{"rendered":"Fetal valproate syndrome"},"content":{"rendered":"<p>Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-108660","post","type-post","status-publish","format-standard","hentry","category-f"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fetal valproate syndrome - Definition of Fetal valproate syndrome<\/title>\n<meta name=\"description\" content=\"Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fetal valproate syndrome - Definition of Fetal valproate syndrome\" \/>\n<meta property=\"og:description\" content=\"Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T10:58:11+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/\",\"name\":\"Fetal valproate syndrome - Definition of Fetal valproate syndrome\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2021-05-26T10:58:11+00:00\",\"dateModified\":\"2021-05-26T10:58:11+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fetal valproate syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fetal valproate syndrome - Definition of Fetal valproate syndrome","description":"Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Fetal valproate syndrome - Definition of Fetal valproate syndrome","og_description":"Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/","og_site_name":"Glossary","article_published_time":"2021-05-26T10:58:11+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/","name":"Fetal valproate syndrome - Definition of Fetal valproate syndrome","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2021-05-26T10:58:11+00:00","dateModified":"2021-05-26T10:58:11+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Fetal valproate syndrome (FVS) is caused by exposure to the anticonvulsant drug (AED) valproic acid (trade name Depakene, Depakote, among others). Valproic acid is a pre\u00ac natal teratogen, and a small percentage of women who take the drug in the first trimester of pregnancy will have off-spring with one or more signs of the syndrome. The effects, particularly craniofacial, of prenatal exposure to valproate are so similar to those of several other AEDs, including carbamazepine, hydantoin, mysoline, and phenobarbital, as to have led to the general descriptive term fetal antiepileptic drug syndrome.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/fetal-valproate-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Fetal valproate syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=108660"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108660\/revisions"}],"predecessor-version":[{"id":108661,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108660\/revisions\/108661"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=108660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=108660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=108660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}